WY14643 | ||||||
Upward Slope | Downward Slope | |||||
No mutation | ΔPPRE-1 | ΔPPRE-2 | No mutation | ΔPPRE-1 | ΔPPRE-2 | |
E max (RLU) | 101 ± 2.56 | 70.6 ± 2.17* | 102 ± 8.65 | - | - | - |
E min (RLU) | 1.32 ± 2.91 | –1.64 ± 3.08 | –17.4 ± 18.2 | 27.6 ± 4.76** | - | - |
EC50 (μM) | 0.013 (0.004–0.023) | 0.045 (0.032–0.064)* | 0.028 (0.008–0.098) | 0.38 (0.20–0.41)** | - | - |
Rosiglitazone | ||||||
Upward Slope | Downward Slope | |||||
No mutation | ΔPPRE-1 | ΔPPRE-2 | No mutation | ΔPPRE-1 | ΔPPRE-2 | |
E max (RLU) | 64.9 ± 2.34 | 61.9 ± 6.66 | 62.1 ± 5.07 | - | - | - |
E min (RLU) | −7.47 ± 3.79 | 1.17 ± 0.05 | 2.94 ± 4.03 | - | - | - |
EC50 (μM) | 0.008 (0.003–0.019) | 0.003 (0.001–1.34) | 0.18 (0.08–0.36)* | - | - | - |